AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Monday.com, Zepp Health, and Credo Technology Group Holding Ltd: Analysts Weigh In With Bullish Sentiments
ByAinvest
Wednesday, Aug 27, 2025 1:02 am ET1min read
Analysts at Oppenheimer, Mizuho Securities, and Fundamental Research have issued bullish reports on Monday.com, Zepp Health, and Credo Technology Group Holding Ltd, respectively. Monday.com has a Strong Buy consensus rating with an average price target of $266.35, a 51.5% upside from current levels. Zepp Health has a Moderate Buy consensus rating with a $52.12 average price target. Credo Technology Group Holding Ltd has a Strong Buy consensus rating with an average price target of $109.36, representing a -5.1% downside.
Analysts at Oppenheimer, Mizuho Securities, and Fundamental Research have issued bullish reports on Monday.com, Zepp Health, and Credo Technology Group Holding Ltd, respectively. Monday.com has a Strong Buy consensus rating with an average price target of $266.35, a 51.5% upside from current levels. Zepp Health has a Moderate Buy consensus rating with a $52.12 average price target. Credo Technology Group Holding Ltd has a Strong Buy consensus rating with an average price target of $109.36, representing a -5.1% downside.Monday.com
Monday.com, a leading provider of work management tools, has received a Strong Buy consensus rating from analysts. The stock has an average price target of $266.35, suggesting a 51.5% upside from its current level. Oppenheimer, one of the analysts issuing the report, has set a $300.00 price target on the stock [2]. The company's recent quarterly earnings report showed a strong performance, with revenue increasing by 26.6% year-over-year and earnings per share (EPS) of $1.09, exceeding analyst expectations [1].
Zepp Health
Zepp Health, a company focusing on health and wellness technology, has been given a Moderate Buy consensus rating by analysts. The average price target for Zepp Health is $52.12. The company's recent growth and innovation in the health tech sector have attracted positive analyst sentiment [1].
Credo Technology Group Holding Ltd
Credo Technology Group Holding Ltd has received a Strong Buy consensus rating from analysts, with an average price target of $109.36. This represents a -5.1% downside from the current level. The company's strong market position and growth prospects in the technology sector have contributed to the positive analyst sentiment [1].
Analyst recommendations should be viewed with caution, as they often reflect the vested interests of brokerage firms. It is essential for investors to conduct their own research and consider other indicators, such as the Zacks Rank, which uses earnings estimate revisions to predict stock price movements [1].
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet